Skip to main content
. 2016 May 10;86(19):1785–1793. doi: 10.1212/WNL.0000000000002649

Table 3.

Adverse events with an incidence of ≥10% in either treatment group (safety set)

graphic file with name NEUROLOGY2015653303TT3.jpg